Aethlon Medical (AEMD) Reports Q2 Loss of $0.16/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Aethlon Medical Announces Fiscal 2016 Second Quarter Results
November 16, 2015 4:01 PM ESTSAN DIEGO, Nov. 16, 2015 /PRNewswire/ --Â Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the second quarter of fiscal 2016 ended September 30, 2015.
"Beyond achieving the short-term objectives set forth in our last quarterly call, we also made material advancements that should benefit our long-term clinical and commercialization endeavors," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "We transitioned to a new Principal Investigator to support our... More
